Phase III study of Pfizer's figitumumab in NSCLC halted
This article was originally published in Scrip
Executive Summary
Pfizer has discontinued a pivotal Phase III trial of its novel insulin-like growth factor 1 (IGF-1) receptor antagonist, figitumumab (CP-751,871), which it was testing as a first-line treatment for non-adenocarcinoma non-small cell lung cancer (NSCLC).